Actively Recruiting
Pioglitazone Therapy Targeting Fatigue in Breast Cancer
Led by West Virginia University · Updated on 2025-04-08
30
Participants Needed
1
Research Sites
257 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to target underlying mechanisms that promote muscle fatigue in patients with breast cancer. This represents an off-label use of this compound, both in terms of the patient population and the clinical phenotype targeted. The central research hypothesis of this study is that daily pioglitazone will restore transcriptional downregulation of pathways within skeletal that promote fatigue.
CONDITIONS
Official Title
Pioglitazone Therapy Targeting Fatigue in Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed luminal (ER+/PR+ Her2/neu-) breast cancer
- No prior therapies except chemotherapy in the neoadjuvant setting
- Planned mastectomy surgery within 2 weeks of starting treatment
- Normal hemoglobin levels within institutional limits
- Normal fasting blood glucose within institutional limits
- Normal serum creatinine within institutional limits
- Normal liver function tests (AST, ALT, alkaline phosphatase, total bilirubin) within limits
- No prior diagnosis of diabetes or use of blood glucose-lowering medications
- Ability to understand and willingness to sign informed consent
You will not qualify if you...
- Prior diagnosis of congestive heart failure, bladder cancer, osteoporosis, or history of bariatric surgery
- Use of other investigational agents or drugs with major interactions with pioglitazone (e.g., clopidogrel, gatifloxacin, gemfibrozil, leflunomide, lomitapide, lumateperone, mipomersen, pexideartinib, teriflunomide, insulin, Lyrica, Synthroid)
- History of allergic reactions to compounds similar to pioglitazone
- Uncontrolled illnesses such as active infection, unstable angina, cardiac arrhythmia, active alcoholism, or psychiatric/social issues limiting compliance
- Pregnant or breastfeeding women due to potential risks to infants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West Virginia University Cancer Institute
Morgantown, West Virginia, United States, 26506
Actively Recruiting
Research Team
K
Kristin Lupinacci, DO
CONTACT
E
Emidio Pistilli, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here